Mountain Valley MD

What Mountain Valley MD does

Mountain Valley MD Holdings Inc. (MVMD) is a Canadian biotech company that develops and commercializes proprietary drug delivery, solubilization, and plant signaling platforms applied across human health, animal husbandry, and agriculture. Headquartered in Toronto and listed on the Canadian Securities Exchange (ticker MVMD.CN) and OTC markets (ticker MVMDF), the company became public in March 2020 following a February 2020 reverse takeover transaction. MVMD operates three core technology platforms: Quicksome™ — a sublingual delivery system that enables needle-free, room-temperature stable delivery of sensitive peptides and biologics (demonstrated with FDA lab confirmation preserving Polio D Antigen); Quicksol™ — a solubilization technology that significantly improves compound solubility, including a 2,500x improvement for ivermectin; and Agrarius™ — an organic plant signaling technology that increases crop yields with reduced fertilizer and pesticide reliance, with Brazil citrus trials showing positive HLB mitigation results.

The company's product portfolio spans Soluvec 1% (commercial-stage antiparasitic fish feed), pipeline products Ivectosol™ (FDA 505(b)(2) pathway) and Selactosol™ (solubilized selamectin), and in-development Quicksome-based peptide formulations targeting BPC-157, GHK-Cu, KPV, SNAP-8, and retatrutide. MVMD's revenue model is hybrid, combining technology licensing royalties (e.g., Quicksome licensed to Eons for the Deeper Sleep nutraceutical), exclusive territorial licensing (Agrarius across the Americas, held since April 2024), and direct or partner-driven product sales in aquaculture (Soluvec via Canada Bangla Agro in Bangladesh) and agriculture (Agrarius via Brazilian distributors). The company sells primarily to compounded pharmacies, nutraceutical brands, agricultural distributors, and aquaculture operators through B2B licensing and channel-partner arrangements.

With 11–50 employees, MVMD is an early-commercialization-stage public company that has not disclosed material revenue and has historically funded operations through small equity placements, most recently a C$2,000,000 non-brokered private placement in April 2026 paired with a C$485,000 shares-for-debt settlement. Its intellectual property position includes a granted Canadian patent for Quicksome, pending patents for Soluvec and a dose-sparing vaccine adjuvant, the Selactosol™ trademark filing, and the exclusive Agrarius Americas license. Notable strategic additions in 2026 include 11 advisory board appointments (including Aubrey Marcus and Bode Miller) and advancement of the Quicksome peptide program targeting the compounded pharmacy market.

Name

Mountain Valley MD

Legal name

Mountain Valley MD Holdings Inc.

Website

https://mountainvalleymd.com

Company type

Public

Founded year

2020

Operating status

Operating

Headcount range

11–50 employees

Short description

Mountain Valley MD is a Toronto-based biotech company developing proprietary drug delivery (Quicksome™), solubilization (Quicksol™), and agricultural signaling (Agrarius™) platforms, commercializing them via licensing and channel partnerships across human health, animal husbandry, and agriculture in the Americas and Bangladesh.

Ownership category

akta.pro rank

Product category

Biopharmaceutical Drug Delivery

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pesticide, Fertilizer, and Other Agricultural Chemical Manufacturing (3253), Farm Supplies Merchant Wholesalers (42491)

SIC

Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833), Agricultural Services (700)

akta.pro primary industry

Bio-based Pharmaceuticals, Nutraceuticals & Specialty Bioactives (EUAAAIAK)

akta.pro secondary industries

Soil Health Activators & Biostimulants (Humates, Amino Acids, Seaweed Extracts) (AFABAKAJ), Parasiticides & Ectoparasite Control (Flea/Tick/Heartworm) (HLAMAEAD), Vitamins (A, B-Complex, C, D, E, K; Premixes) (AFAJAKAA), Organic & Biological Input Retail (Biostimulants, Biopesticides, OMRI) (AFABAJAK)

Keywords

• Sublingual drug delivery
• Pharmaceutical solubilization
• Agricultural biotechnology
• Aquaculture health products
• Peptide delivery systems

Headquarters

HQ city

Vancouver

HQ country

Canada

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Marketing or Sales, Operations

Revenue model

1. Technology Licensing: MVMD licenses its proprietary technologies (Quicksome, Quicksol, Agrarius) to commercial partners for use in their products, generating licensing fees and royalty revenue.
2. Product Sales - Agriculture: Direct commercial sales of Agrarius agricultural products to farmers and agricultural businesses for crop yield enhancement.
3. Product Sales - Animal Health: Commercial sales of Soluvec fish feed products and other animal health solutions through partners like Canada Bangla Agro.
4. Nutraceutical Products: Sales of enhanced nutraceutical products using Quicksome technology, such as the Eons Deeper Sleep product.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels4 records

Core offering

Mountain Valley MD develops and commercializes proprietary biotechnology and drug delivery platforms — Quicksome™ (sublingual/needle-free delivery of peptides, vaccines, and nutraceuticals), Quicksol™ (compound solubilization for animal health, including ivermectin 2,500x more soluble), and Agrarius™ (organic plant signaling technology for crop yield enhancement). The company licenses these technologies to commercial partners and directly sells formulated products such as Soluvec 1% (aquaculture antiparasitic) and Agrarius agricultural inputs across the Americas and select international markets.

Product overview

MVMD is a biotech company offering three core technology platforms: Quicksome™ (sublingual/needle-free delivery for peptides, vaccines, and drugs), Quicksol™ (compound enhancement for animal health), and Agrarius™ (agricultural signaling technology for crop yield improvement). The company's product portfolio includes commercial products like Soluvec 1% for aquaculture, and pipeline products including Ivectosol™ and Selactosol™. The technologies are designed to solve solubility and delivery challenges across human health, animal husbandry, and agriculture sectors.

Differentiator

Problem solved

Functional benefit

Brands

• Quicksome: Sublingual delivery platform technology for enhanced bioavailability of compounds including peptides, vaccines, and pharmaceuticals
• Quicksol
• Agrarius
• Soluvec

Products and services

• Quicksome™ Sublingual Delivery Platform Proprietary sublingual/needle-free drug delivery technology enabling stable, room-temperature delivery of peptides (BPC-157, GHK-Cu, KPV, SNAP-8, retatrutide), vaccines, and nutraceuticals with enhanced bioavailability. Licensed to commercial partners for incorporation into their products.
• Quicksol™ Solubilization Technology Proprietary compound solubilization technology that dramatically increases the solubility and absorption of drugs (e.g., 2,500x more soluble ivermectin, 800% absorption increase). Applied in animal health and aquaculture products such as Soluvec and Selactosol.
• Agrarius™ Agricultural Signaling Technology Organic plant signaling technology that helps farmers increase crop yields with reduced reliance on fertilizer and pesticides. Targets crop disease management including HLB (citrus greening) mitigation. Demonstrated positive results in Brazil citrus trials.
• Soluvec 1% Highly solubilized ivermectin formulation (2,500 times more soluble than standard ivermectin) designed as an antiparasitic coated feed for fish and aquaculture applications, improving absorption and efficacy.
• Ivectosol™ Ivermectin-based formulation being developed through the FDA 505(b)(2) regulatory pathway for animal health applications, leveraging Quicksol solubilization technology.
• Selactosol™ Solubilized selamectin formulation addressing solubility challenges common with avermectin-class drugs, intended for animal health applications.

Quantifiable outcome

• 800% increase in ivermectin absorption with Quicksol solubilization technology
• +4 more outcomes

Named customers3 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Four partnerships are on record, tiered core and major.

• Advisory Board (Aubrey Marcus, Bode Miller, Shawn Wells, et al.)coreOthers · 17 April 2026Appointed 11 strategic advisors including Aubrey Marcus (Onnit founder), Olympic skier Bode Miller, and nutraceutical formulator Shawn Wells to provide advisory services across human health, agriculture, formulation science, and capital markets. Additional advisors include Emily Kaplan, Janet Zand, Mark Gelnaw, Alex Wolfe, Dan Engle, Domingos S. S. Junior, and Luis Felipe Scarpa Street bringing expertise in regulatory affairs and biotechnology commercialization.
• Canada Bangla AgromajorChannel Partner/ Reseller/ Distributor · 4 April 2024Partnership for Soluvec fish feed production and distribution in Bangladesh, enabling commercial launch of antiparasitic coated feed using MVMD's solubilization technology.
• EonscoreOEM/ Whitelabel/ Licensing Partner · 28 December 2023Eons launched Deeper Sleep product powered by Quicksome™ sublingual delivery technology, representing a consumer product application of MVMD's drug delivery platform.
• Agrarius Technology PartnercoreStrategic or Co-development Partner · 13 September 2022Exclusive license and distribution agreement for Agrarius technology across Canada, USA, Mexico, South America, Central America, and Caribbean. MVMD retains global non-exclusive rights outside this exclusive territory. Includes performance guarantee program for farmers.

Scale indicators6 records

Recent moves8 records

Expansion highlights5 records

Market position

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/MeadowBay_Gold
• Facebookfacebook.com/Meadow-Bay-Gold-Corp-197526263680250
• LinkedInlinkedin.com/company/mvmd

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds2 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Mountain Valley MD